AstraZeneca PLC (LON:AZN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

AstraZeneca PLC (LON:AZN) has received a consensus rating of “Moderate Buy” from the nine brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is £105.53 ($136.86).

A number of equities research analysts have issued reports on AZN shares. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a £110 ($142.65) price objective on shares of AstraZeneca in a research report on Tuesday, June 18th. Barclays restated an “overweight” rating and set a £125 ($162.11) price objective on shares of AstraZeneca in a research report on Monday, April 8th. Shore Capital restated a “buy” rating on shares of AstraZeneca in a research report on Friday, July 12th. Citigroup reiterated a “buy” rating on shares of AstraZeneca in a report on Tuesday, May 28th. Finally, Berenberg Bank increased their price target on AstraZeneca from £130 ($168.59) to £150 ($194.53) and gave the stock a “buy” rating in a report on Friday, June 7th.

AstraZeneca Trading Down 0.2 %

Shares of AZN stock opened at £121.06 ($157.00) on Friday. AstraZeneca has a 1 year low of GBX 9,461 ($122.69) and a 1 year high of £127.04 ($164.75). The company has a debt-to-equity ratio of 92.51, a current ratio of 0.89 and a quick ratio of 0.59. The stock’s 50 day simple moving average is £122.75 and its two-hundred day simple moving average is £112.48. The company has a market cap of £187.64 billion, a PE ratio of 3,880.13, a price-to-earnings-growth ratio of 0.97 and a beta of 0.16.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.